Journal article
Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first‐line therapy in patients with advanced nonsmall cell lung carcinoma
Abstract
BACKGROUND: Pemetrexed disodium (Alimta [Eli Lilly and Company, Indianapolis, IN], LY231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. Phase II trials showed single-agent response rates of 16% and 23% in untreated patients with nonsmall cell lung carcinoma (NSCLC). This study was undertaken to determine the response to pemetrexed disodium given in combination with …
Authors
Shepherd FA; Dancey J; Arnold A; Neville A; Rusthoven J; Johnson RD; Fisher B; Eisenhauer E
Journal
Cancer, Vol. 92, No. 3, pp. 595–600
Publisher
Wiley
Publication Date
August 1, 2001
DOI
10.1002/1097-0142(20010801)92:3<595::aid-cncr1359>3.0.co;2-d
ISSN
1097-0142